Valuation: GRAIL, Inc.

Capitalization 2.12B 1.8B 1.65B 1.56B 2.9B 196B 2.95B 19.36B 7.59B 95.14B 7.96B 7.79B 335B P/E ratio 2026 *
-4.67x
P/E ratio 2027 * -4.78x
Enterprise value 1.38B 1.17B 1.07B 1.02B 1.88B 128B 1.92B 12.58B 4.93B 61.82B 5.17B 5.06B 218B EV / Sales 2026 *
7.64x
EV / Sales 2027 * 7.44x
Free-Float
86.25%
Yield 2026 *
-
Yield 2027 * -
1 day+4.53%
1 week+13.32%
Current month+0.06%
1 month+9.16%
3 months-46.53%
6 months-33.71%
Current year-39.58%
1 week 45.14
Extreme 45.14
52.44
1 month 44.06
Extreme 44.06
55.36
Current year 41.5
Extreme 41.5
118.84
1 year 26.05
Extreme 26.05
118.84
3 years 12.33
Extreme 12.33
118.84
5 years 12.33
Extreme 12.33
118.84
10 years 12.33
Extreme 12.33
118.84
Manager TitleAgeSince
Chief Executive Officer 66 2021-10-13
Director of Finance/CFO 48 2021-10-31
President 62 2021-05-31
Director TitleAgeSince
Director/Board Member 62 2026-03-11
Director/Board Member 66 2024-06-20
Director/Board Member 58 2024-06-20
Change 5d. change 1-year change 3-years change Capi.($)
+4.53%+13.32%+91.52% - 2.03B
+2.22%+5.51%+0.78%-7.93% 47.35B
+0.99%+4.59%+40.22%+22.31% 35.57B
-0.43%+54.13%+304.33%+504.92% 31.16B
-0.72%+3.91%+35.55%+29.11% 29.62B
+2.62%+5.45%+22.62%-12.91% 28.86B
-6.22%-0.52%+3,641.35%+3,836.02% 15.12B
+0.63%+2.17%+48.12%+195.41% 15.01B
+0.96%+5.48%+75.71%+166.26% 14.73B
+0.87%+8.85%+40.89%+13.56% 14.34B
Average +0.55%+9.18%+430.11%+527.42% 23.38B
Weighted average by Cap. +0.57%+10.97%+300.74%+346.07%

Financials

2026 *2027 *
Net sales 180M 153M 141M 133M 247M 16.69B 251M 1.65B 645M 8.09B 676M 662M 28.51B 222M 188M 173M 164M 304M 20.56B 309M 2.03B 795M 9.97B 834M 816M 35.13B
Net income -470M -398M -367M -347M -643M -43.52B -654M -4.29B -1.68B -21.1B -1.76B -1.73B -74.35B -467M -395M -364M -344M -638M -43.19B -649M -4.26B -1.67B -20.94B -1.75B -1.71B -73.8B
Net Debt -743M -629M -579M -548M -1.02B -68.74B -1.03B -6.78B -2.66B -33.32B -2.79B -2.73B -117B -469M -397M -365M -346M -641M -43.37B -652M -4.28B -1.68B -21.03B -1.76B -1.72B -74.11B
Logo GRAIL, Inc.
GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.
Employees
910
Date Price Change Volume
26-04-17 51.71 $ +4.53% 740,467
26-04-16 49.47 $ -0.64% 520,752
26-04-15 49.79 $ -1.39% 565,373
26-04-14 50.49 $ +5.10% 558,202
26-04-13 48.04 $ +5.28% 547,018
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
51.71USD
Average target price
67.71USD
Spread / Average Target
+30.95%

Quarterly revenue - Rate of surprise